Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL9388385 | 0.92 | TLR7 (0.63) | TLR7PDE4DPOLBNUDT1LMNA | |
| Butyric Acid SCHEMBL9388409 | 0.89 | TLR7 (0.61) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL14667666 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL4830500 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL29378640 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA | |
| Imiquimod SCHEMBL570774 | 0.85 | TLR7 (1.00) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL1774937 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL4562038 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL1774913 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA | |
| SCHEMBL29376434 | 0.85 | TLR7 (0.72) | TLR7PDE4DPOLBNUDT1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| EP-3950687-A1 | INDUSTRIAL METHOD FOR SYNTHESISING IMIQUIMOD FROM QUINOLINE-2,4-DIOL APPLICABLE TO THE PHARMACEUTICAL USE THEREOF | PHV Pharma (FR) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021007160-A1 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | TAMBO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020141221-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | ASCENDIS PHARMA A/S (DK) | 2020-07-09 | — | — | WO | disclosed |
| US-20140220063-A1 | VACCINE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20130028857-A1 | SYNTHETIC NANOCARRIERS COMPRISING POLYMERS COMPRISING MULTIPLE IMMUNOMODULATORY AGENTS | SELECTA BIOSCIENCES, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-7687628-B2 | Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | TLR7 9/4885PDE4D 1254/4885POLB 2760/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | TLR7 57/4885PDE4D 1415/4885POLB 3885/4885 |
| US-20130028857-A1 | SYNTHETIC NANOCARRIERS COMPRISING POLYMERS COMPRISING MULTIPLE IMMUNOMODULATORY AGENTS | CD47, IFNG, IL2 | TLR7 84/4885PDE4D 2558/4885POLB 2849/4885 |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, TAP1, MICA | TLR7 259/4885PDE4D 3464/4885POLB 2418/4885 |
| US-20140220063-A1 | VACCINE COMPOSITION | MYD88, IRF3, CD14 | TLR7 56/4885PDE4D 2885/4885POLB 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.